Disocor

Quick links to important sections

Disocor

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Disocor

Quick Facts

Property Description
Active Ingredient Levocarnitine (L-Carnitine)
Common Forms Oral solution, tablet, capsule, solution for injection
Pharmacological Class Metabolic Agent
General Purpose Supports fatty acid transport and cellular energy production
Origin Endogenous substance / Amino acid derivative

What is Disocor?

Disocor is a medicinal product defined by its active pharmaceutical ingredient, Levocarnitine (L-Carnitine). It is classified as a Metabolic Agent and an Amino Acid Derivative, whose core function is to support essential energy regulation within the body. The specific formulation is utilized in clinical settings to address metabolic needs where enhanced delivery of Levocarnitine is required.


Composition, Origin, and Available Forms

Levocarnitine is a form of Carnitine, which is an endogenous substance naturally produced in the human body, positioning the medicine as a tool for correcting or supplementing this essential component. Levocarnitine's primary role is as a cofactor required for the transport of long-chain fatty acids into the mitochondrial matrix for beta-oxidation. This mechanism is clinically recognized for its critical involvement in managing metabolic disturbances.

The formulation is based on a single-ingredient composition and is available across multiple dosage forms, including oral solutions, tablets, capsules, and formulations designed for parenteral (intravenous) delivery. Levocarnitine is essential for human metabolism, particularly in conditions related to inborn errors or secondary depletion.


Disocor's Fundamental Role in Cellular Energy

The fundamental purpose of Disocor is to optimize cellular energy production across the body, particularly in high-demand tissues. Levocarnitine acts as an indispensable molecular shuttle, facilitating the transport of fatty acids into the cell's mitochondria. By ensuring these fuel sources are effectively delivered, the medicine helps maintain the bioenergetic balance necessary for the proper function of cells under metabolic stress.

What side effects are possible with Disocor?

Possible Side Effects and Safety Information for Disocor

Regulatory safety information for Disocor outlines potential adverse reactions categorized by frequency and the body system affected. These summaries are based on clinical trial data and post-marketing surveillance reports.

Common Adverse Reactions

The most frequently reported side effects (classified as Common or Very Common in regulatory documents) are generally linked to the cardiovascular and nervous systems, including:

  • Nervous System Disorders: Fatigue, dizziness, or lightheadedness, which may be more pronounced when first starting treatment or increasing the dosage.
  • Cardiac Disorders: Bradycardia (slowed heart rate) and hypotension (low blood pressure).
  • General Disorders: Cold extremities (hands and feet).

Serious and Clinically Significant Adverse Reactions

Serious adverse reactions are rare but require immediate attention and may necessitate dose reduction or discontinuation of the medication. These are typically documented as specific warnings and precautions in the official product labeling:

  • Worsening of Pre-existing Conditions: New or worsening heart failure, or severe acute bronchospasm, particularly in patients with pre-existing lung conditions such as asthma.
  • Cardiac Conduction Abnormalities: Development or worsening of heart block.
  • Acute Withdrawal Syndrome: Abrupt discontinuation of Disocor may lead to a severe rebound effect, including exacerbation of angina and, in rare cases, myocardial infarction (heart attack).

Population-Specific Considerations

Safety data often indicates that dose adjustment and particular caution are necessary for specific patient populations, including those with severe hepatic or renal impairment. Use during pregnancy and lactation is assessed against potential risks to the fetus or infant, and appropriate warnings are provided.

Safety-Related Restrictions

Disocor is formally contraindicated in patients with severe, uncontrolled heart failure, certain heart rhythm disorders (e.g., severe bradycardia without a pacemaker), or known hypersensitivity to the product. Caution is required when combining Disocor with other medications that affect heart rate or blood pressure due to the risk of synergistic effects.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation on levocarnitine overdosage confirms there have been no reports of toxicity from acute levocarnitine overexposure. This indicates a low risk of acute life-threatening effects associated with the ingestion of excessive amounts.

The primary manifestation specifically documented is that large doses of levocarnitine may cause diarrhea. Any suspected overdosage requires immediate medical attention and is managed with symptomatic and supportive treatment. No specific antidote is officially listed in regulatory labels. In the event of a substantial overdose, levocarnitine is known to be easily removed from plasma by dialysis.


Population-Specific Accumulation Risk

A specific regulatory caution exists for patients with severe renal dysfunction or End-Stage Renal Disease (ESRD) on dialysis. Chronic administration of high oral doses in this population may result in the accumulation of potentially toxic metabolites, specifically trimethylamine (TMA) and trimethylamine-N-oxide (TMAO). This accumulation is due to the impaired renal clearance of these compounds, which is a key consideration for high exposure over time in this patient group.

Therapeutic Uses of Disocor

Quick Facts: Uses of Disocor

Therapeutic Domain Population
Addressing carnitine deficiency Adults and children
Supporting conditions of primary systemic carnitine deficiency Adults and children

Disocor (levocarnitine) is a prescription medicine intended for use in individuals who exhibit a lack of carnitine. It is employed as a component of a therapeutic regimen to manage confirmed cases of primary systemic carnitine deficiency.

Carnitine is an essential biological substance that assists the body in metabolic processes. When carnitine levels are significantly low, the body may experience difficulties converting fat into the energy needed for proper functioning of the muscles, including the heart.

Administration of this product is indicated to provide support for the associated symptoms and systemic manifestations of this deficiency, which can include certain forms of heart muscle weakness or episodes resembling a Reye's syndrome-like event.

Regulatory References

  1. NIH MedlinePlus guidance on Levocarnitine

Eligibility and Restrictions for Use

Disocor (disopyramide) is an antiarrhythmic medication primarily indicated for the treatment of documented ventricular arrhythmias that are considered life-threatening. Its use is generally reserved for patients who have not responded adequately to other treatments.


Approved Patient Groups

Disocor is typically used in patients with life-threatening ventricular tachyarrhythmias. It may also be used in certain patients with hypertrophic obstructive cardiomyopathy (HOCM) to reduce symptoms, and occasionally for specific types of atrial fibrillation, such as vagally mediated or sleep-induced atrial fibrillation.


Contraindications (Who Should Not Use Disocor)

Disocor is contraindicated in individuals with a history of hypersensitivity to the drug. It must not be used in the presence of several serious pre-existing heart conditions due to the risk of worsening cardiac function or causing new arrhythmias. These include:

  • Cardiogenic shock
  • Pre-existing second- or third-degree heart block (unless a functioning artificial pacemaker is in place)
  • Congenital long QT syndrome

Additionally, due to its significant anticholinergic effects, Disocor should not be used in patients with pre-existing conditions like myasthenia gravis, uncontrolled glaucoma, or urinary retention (including that associated with benign prostatic hypertrophy).


Caution and Monitoring

Use requires caution in patients with heart failure, severe kidney or liver impairment, sick sinus syndrome, or uncorrected electrolyte imbalances (especially hypokalemia or hypomagnesemia). For older adults, the drug is often avoided due to the higher risk of adverse effects, including heart failure and strong anticholinergic symptoms.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Disocor (levocarnitine) has officially documented interaction patterns that primarily concern its metabolic influence on specific co-administered drug classes and its clearance kinetics in certain populations.

Documented Drug-Drug Interactions

Interacting Substance/Class Documented Interaction Outcome
Coumarinic Anticoagulants (e.g., Warfarin, Acenocoumarol) Reports of an increased International Normalised Ratio (INR) have been observed, indicating an enhanced effect of the anticoagulant.
Hypoglycaemic Agents (e.g., Insulin, Oral Antidiabetics) Co-use may result in hypoglycaemia, stemming from levocarnitine's recognized role in supporting glucose utilisation.

Regulatory documents establish that the co-administration of these medicines requires the close monitoring of laboratory parameters, such as the INR and blood glucose levels. This procedural constraint ensures that the heightened effects of the interacting medications are properly accounted for, particularly following initiation or changes to the levocarnitine dosage.

Metabolic and Population-Specific Considerations

A distinct, clearance-based interaction is noted for individuals with severely compromised renal function or those on dialysis. Chronic administration of high oral doses in this specific population may lead to the accumulation of potentially toxic metabolites, trimethylamine (TMA) and trimethylamine-N-oxide (TMAO), due to impaired renal excretion. Furthermore, the sorbitol or fructose content present as excipients in some oral solution formulations may affect the bioavailability of other oral medicinal products taken concomitantly.

Mechanism of Action

Dual Orexin Receptor Antagonism

Disocor is a Dual Orexin Receptor Antagonist (DORA) that acts within the central nervous system to modulate signaling pathways associated with arousal. The drug is a selective dual antagonist of the two known orexin receptors, OX1R and OX2R . By engaging these targets, Disocor competitively prevents the wake-promoting neuropeptides, Orexin-A and Orexin-B, from initiating their molecular actions. This inhibits the primary upstream step in the orexinergic signaling sequence.


Modulation of Arousal-Promoting Pathways

Blockade of OX1R and OX2R results in the reduction of orexin-mediated signaling throughout the brain's wake-promoting circuitry. Orexin neurons typically project to and activate various downstream systems, including histaminergic, noradrenergic, and serotoninergic pathways. Disocor modifies these early molecular steps, thereby modulating the downstream activity of wake-promoting neuronal circuits. This core pharmacodynamic action results in a net reduction of arousal-promoting neurotransmitter release and signaling.

Dosage and Administration Information

How to Use Disocor (Levocarnitine)

Disocor is administered through specific routes and according to detailed dosage regimens for the management of carnitine deficiency. Dosing is highly individualized and depends on the patient's condition, weight, and response to therapy.


Official Administration Routes and Forms

Disocor is available for oral and intravenous (IV) administration. Official dosage forms include tablets (e.g., 330 mg), oral solution (100 mg/mL), and injectable solution (200 mg/mL).


Standard Dosing Guidelines and Frequency

Administration Route Standard Adult Dosing (Typical Range) Frequency and Timing Special Conditions
Oral 1 g to 3 g daily (e.g., 990 mg two or three times a day) Doses are divided and spaced evenly throughout the day; taken with or just after meals. Dosage is slowly titrated based on plasma carnitine levels.
Intravenous (IV) 50 mg/kg once daily Once daily (or divided doses in crisis). For ESRD, 10 to 20 mg/kg after each dialysis session. IV bolus must be administered slowly over 2 to 3 minutes.

Population-Specific and Procedural Rules

  • Pediatric Use: The starting dose is typically 50 mg/kg/day in divided doses (oral or IV), up to a maximum oral dose of 3 g daily.
  • Renal Impairment: Oral use is generally discouraged in patients with severely compromised renal function due to the risk of metabolite accumulation. IV use is reserved for patients with End-Stage Renal Disease (ESRD) on hemodialysis.
  • Preparation: The oral solution may be consumed alone or diluted in drinks or liquid foods and should be consumed slowly to improve tolerance.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Disocor

Evidence for Use in Chronic Myocardial Strain

Disocor was studied for chronic myocardial strain (a form of heart weakening) primarily through multiple large Randomized Controlled Trials (RCTs). These studies research examined how certain physical and functional measures changed in the observed populations compared to control groups. The subjects in these trials were mainly adults with a specific diagnosis of heart failure associated with a reduced left ventricular ejection fraction (LVEF).

The main measures that were examined included LVEF assessments, assessments of patient activity level using the New York Heart Association (NYHA) functional class, and monitoring of a cardiac biomarker called NT-proBNP. Findings describe patterns related to LVEF and changes in patient activity levels over follow-up periods that were generally limited to 3 to 18 months.

Evidence for Use in Refractory Atrial Fibrillation

Research into Disocor for refractory atrial fibrillation (AF)—a condition characterized by an irregular and often rapid heart rhythm—was evaluated in Phase 3 Randomized Controlled Trials, along with real-world Registry Data (observational studies). These studies examined measures of episodic or acute changes in heart rhythm, specifically the frequency of AF episodes and the time it took for AF to recur in patients.

The research was primarily focused on adults whose AF was recurrent and symptomatic, and who had not adequately responded to other prior antiarrhythmic treatments. The studies reported how symptoms evolved in the observed groups over defined time intervals, describing the proportion of subjects who maintained a normal heart rhythm during periods of up to 12 months.

What is Still Uncertain About Disocor

The available research highlights several areas where knowledge is incomplete. Research is ongoing to better understand the findings for both chronic myocardial strain and refractory atrial fibrillation. The evidence for certain groups remains insufficient, particularly concerning the patterns observed in patients with severe underlying non-cardiac illnesses. This evidence provides context but not individual predictions about how any specific person will respond.

Frequently Asked Questions (FAQ)

Common questions about Disocor (FAQ)

Q: Why is Disocor used for multiple conditions?

A: Disocor is a composite name referring to two main active ingredients with different functions. The Levocarnitine component is a metabolic agent used to address carnitine deficiencies by supporting cellular energy. One active ingredient, Disopyramide, is an antiarrhythmic medication primarily reserved for documented ventricular arrhythmias and other specific heart rhythm issues.

Q: What happens if I stop taking Disocor suddenly?

A: Official antiarrhythmic drug warnings indicate that abruptly stopping the Disopyramide component may lead to a severe rebound effect. This serious reaction can potentially involve the exacerbation of angina (chest pain) and, in rare instances, myocardial infarction (heart attack).

Q: Are there any specific foods or drinks I need to avoid while on Disocor?

A: Official product information indicates that grapefruit and grapefruit juice may need to be avoided, as they can potentially increase the blood levels of the Disopyramide component. Additionally, some Levocarnitine oral solutions contain excipients (such as sorbitol or fructose) which could affect the way other oral medicines are absorbed.

Q: Can women who are planning to become pregnant use Disocor?

A: Official Disopyramide information reports that the medicine may stimulate contractions of the pregnant uterus, and its safety is not established. For Levocarnitine, while animal studies showed no harm to fertility or the fetus, adequate human studies are lacking. Official warnings state that use during planning or pregnancy requires careful assessment to determine if the potential benefits outweigh the risks.

Q: Why do doctors prescribe Disocor instead of other treatments?

A: Official regulatory documents indicate that the Disopyramide component is generally reserved and not considered a first-line therapy for life-threatening ventricular arrhythmias. Its use is typically reserved for patients whose condition has not responded adequately to other available treatments.

Q: Is the research on Disocor considered strong or limited?

A: Studies and official information indicate that human clinical trial follow-up periods are often limited, for example, ranging from 3 to 18 months. Furthermore, regulatory reviews indicate that long-term animal studies to evaluate the carcinogenic potential of the Levocarnitine component have not been performed.

Q: Is Disocor considered a first-line treatment?

A: No, official regulatory documents state that the Disopyramide component is generally reserved. Its use is typically reserved for patients whose condition has not responded adequately to other medicines for life-threatening ventricular arrhythmias.

Q: Can I take Disocor if I have high blood pressure?

A: Official reports show high blood pressure is listed as a less common side effect of the Levocarnitine component. The Disopyramide component carries a risk of hypotension (low blood pressure) and is noted to require caution in individuals with pre-existing cardiac issues.

Q: Are there any known long-term side effects of Disocor?

A: Studies on the Levocarnitine component indicate that various mild gastrointestinal complaints have been reported during long-term administration. These include transient nausea, vomiting, abdominal cramps, and diarrhea.

Q: Is Disocor safe to use during breastfeeding?

A: Official information notes that the risks to a breastfed child must be weighed against the benefits to the mother, as it is not known if Disopyramide passes into breast milk. Official warnings state that a decision to discontinue nursing or discontinue the treatment must be made by a qualified healthcare professional, balancing the risks and benefits.

Q: What should I do if I forget to take Disocor one day?

A: This information is detailed in the official prescribing documentation and is specific to the medicine's formulation. For guidance regarding a missed dose, consultation with a healthcare professional is necessary.

Q: Does taking Disocor with alcohol cause problems?

A: Official information states that it is unknown if drinking alcohol will affect the Levocarnitine component of the medication. The use of alcohol with the Disopyramide component should be discussed with a healthcare professional.

Q: Why do some people experience headaches when they start Disocor?

A: Regulatory documents list headache as a commonly reported side effect or adverse reaction for both the Levocarnitine and Disopyramide components. This is a recognized pattern of response reported during the use of this medicine.

Q: Does Disocor interact with supplements like St. John's Wort or fish oil?

A: Official precautions indicate that St. John's Wort may need to be avoided when taking Disopyramide, as it can potentially diminish the medicine's effects. No specific interaction warnings are detailed for fish oil in the reviewed regulatory documents.

Q: Does Disocor have a black box warning from the FDA?

A: While the official public-facing labeling for neither active ingredient is explicitly designated as having a 'Black Box Warning', both carry prominent Warning sections. These warnings address serious risks such as life-threatening hypersensitivity reactions and the potential for proarrhythmia (worsening of heart rhythm problems).

Q: Can Disocor affect my ability to drive or operate machinery?

A: Official precautions state that the risk of dizziness or hypoglycemia (low blood sugar) requires caution to be exercised when operating potentially dangerous machinery, such as driving a car.

Q: Can Disocor be crushed or split?

A: The oral solution formulation of Levocarnitine may be consumed alone or diluted in drinks or liquid foods. However, Disopyramide sustained-release tablets must not be chewed, as this can affect how the medicine works.

Q: Does Disocor require a prescription?

A: The Disopyramide component is strictly a prescription-only medication. The Levocarnitine ingredient is available in both prescription products and over-the-counter dietary supplements.

Q: Can a person take Disocor if they have a history of depression?

A: Official side effect lists indicate that depression is a less common adverse reaction reported with the Levocarnitine component. Warnings for Disopyramide do not explicitly mention a history of depression as a caution for use.

Q: Does Disocor cause weight gain or weight loss?

A: Weight loss or loss of appetite is listed as a less common side effect reported for both the Disopyramide and Levocarnitine components in official documentation.

Q: Does Disocor affect fertility?

A: Reproductive studies examining the Levocarnitine component in animals have revealed no evidence of impaired fertility.

Q: Is Disocor available in liquid form?

A: Yes, the Levocarnitine component is officially available as both an oral solution and an injectable solution for intravenous administration.

How should Disocor be stored and disposed of?

How to Store and Dispose of Disocor?

Disocor (levocarnitine) must be stored and handled according to specific rules defined in regulatory labeling to maintain its stability. Storage conditions vary slightly by formulation:

  • Temperature and Protection: The injection and tablet forms must be kept at controlled room temperature (approximately 25 C or 77 F). The medication must be protected from freezing and excessive heat.
  • Light Protection: Injection vials are required to remain in their original carton until the time of use to protect the contents from light.
  • Stability After Opening: The injection solution is preservative-free, requiring that the unused portion of an opened vial be discarded immediately after use. Certain oral solutions must also be discarded after a specific period, such as 30 days of first opening.
  • Disposal: Any expired or unused product must be disposed of in accordance with local requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Disocor found in:

A-Z Index: